Addressing the Issue of Genomic Stability in iPSCs: New Approach for Restoring Cell Lines

Life Sciences, Drug Discovery & Development, Laboratory Technology, Fundamental Research, Cell and Gene Therapy,
  • Wednesday, June 12, 2024

Induced pluripotent stem cells (iPSCs) have revolutionized cell-based therapeutics, drug discovery and many other scientific fields. However, despite significant advancements in iPSC culture, several challenges remain regarding the reliability, reproducibility and consistency of cell cultures, assays and data. These challenges not only lead to significant costs and time on projects but also affect the quality of the final product.

This webinar focuses on the different types of quality control (QC) required for iPSCs, with an emphasis on the International Society for Stem Cell Research (ISSCR) standards guidance. Genomic stability assessment is a crucial part of QC since up to 30 percent of cultures have genomic or genetic changes that can affect downstream usage with significant implications for cell-based therapeutics.

To address these challenges, the expert speakers will focus on a novel solution that recovers iPSC lines with mosaic genomic or genetic abnormalities. Cellected Ltd.’s novel solution, RESCUE, combines high-throughput single-cell cloning with the Advanced Instruments VIPS® PRO and rapid genomic screening to recover normal cells from the population. The Cell Metric® X platform enhances clone selection and growth analytics and, combined with bespoke functional QC, enables the rapid return of the normal cell line to customers.

Register for this webinar to learn about the latest advancements in iPSC culture and quality control and take the first step towards improving the reproducibility, reliability and consistency of cell cultures, assays and data.


Claire Richards, Cellected

Claire Richards, PhD, CEO, Cellected

Claire Richards completed her PhD from the Welcome Trust Sanger Institute, Cambridge University, which is a part of the Cancer Genome Project. She subsequently joined Horizon Discovery (now Revvity) as Team Leader in Cell Line Engineering, using CRISPR and rAAV editing techniques, and was the Head of Biology at Solentim, where she developed expertise in automated single-cell cloning, imaging and developed their iPSC workflow.

Currently serving as the CEO at Cellected, Claire leads strategic initiatives to revolutionize bioprocessing methodologies tailored to iPSCs. Her visionary leadership and technical acumen have been instrumental in propelling Cellected to the forefront of the industry.

Message Presenter
Marta Rucka, Advanced Instruments, LLC

Marta Rucka, PhD, Global Product Lead, Advanced Instruments, LLC

Marta Rucka has extensive experience in cell biology with a particular interest in mechanisms driving cancer development and differentiation of stem cells. She received her PhD from the University of Southampton in 2014 and worked in a commercial role leading product management and development in cell-based assays, 3D cell culture and instrumentation. In early 2022, Marta joined Advanced Instruments focusing on the Solentim portfolio of solutions for single-cell seeding and clonal outgrowth monitoring, which employ both cell biology and artificial intelligence.

Message Presenter

Who Should Attend?

This webinar will appeal to:

  • Stem cell scientists and researchers working in cell line development and/or development of stem cell-derived cell therapies
  • Researchers and specialists in cell line development seeking to improve clonality assurance, genetic stability and quality control in their stem cell workflow
  • Biotechnologists and cell line development professionals focused on advanced therapeutics and high-throughput screening, especially those working with challenging cell lines like iPSCs and MSCs

What You Will Learn

Attendees will learn about:

  • Challenges in iPSC Culture: Despite advancements, challenges persist in maintaining reliability, reproducibility and consistency in iPSC culture
  • Genomic Stability Assessment: Up to 30 percent of iPSC cultures may exhibit genomic or genetic changes, which can significantly impact downstream usage, especially in cell-based therapeutics
  • Improving Reproducibility and Reliability: By implementing the right approach supported by the latest technologies, it is possible to enhance the reproducibility, reliability and consistency of iPSCs during culture and cell therapies’ development

Xtalks Partner

Advanced Instruments

Advanced Instruments is a global company offering a novel portfolio of analytical tools including, OsmoTECH®, a robust line of micro-osmometers to support bioprocessing and quality control (QC), and Solentim, a portfolio of best in class imaging and single-cell deposition technologies for cell line development workflows and assurance of clonality for regulatory bodies.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account